Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $281.4 million.

  • Cellebrite DI's Cash & Equivalents rose 10635.35% to $281.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.4 million, marking a year-over-year increase of 10635.35%. This contributed to the annual value of $191.7 million for FY2024, which is 113.02% up from last year.
  • As of Q3 2025, Cellebrite DI's Cash & Equivalents stood at $281.4 million, which was up 10635.35% from $179.2 million recorded in Q2 2025.
  • Over the past 5 years, Cellebrite DI's Cash & Equivalents peaked at $281.4 million during Q3 2025, and registered a low of $84.6 million during Q3 2022.
  • For the 5-year period, Cellebrite DI's Cash & Equivalents averaged around $149.1 million, with its median value being $146.0 million (2021).
  • As far as peak fluctuations go, Cellebrite DI's Cash & Equivalents soared by 11623.25% in 2023, and later plummeted by 5226.02% in 2025.
  • Over the past 5 years, Cellebrite DI's Cash & Equivalents (Quarter) stood at $146.0 million in 2021, then crashed by 39.96% to $87.6 million in 2022, then surged by 116.23% to $189.5 million in 2023, then rose by 1.13% to $191.7 million in 2024, then soared by 46.8% to $281.4 million in 2025.
  • Its last three reported values are $281.4 million in Q3 2025, $179.2 million for Q2 2025, and $90.5 million during Q1 2025.